Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 56, Issue 11, 2001, Pages

  Meneilly, Graydon S ^a   McIntosh, Christopher H S ^a   Pederson, Raymond A ^a   Habener, Joel F ^b,e   Gingerich, Ronald ^c   Egan, Josephine M ^d,e   Elahi, Dariush ^d,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c Linco Research   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-37] AMIDE; GLUCOSE; INSULIN; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

AGED; AGING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN INFUSION; INSULIN RELEASE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; PEPTIDE FRAGMENTS; PEPTIDES;

EID: 0034766032     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/56.11.M681     Document Type: Article

References (26)

1. Glucagon-like peptide-1, a new hormone of the entero-insular axis
2. Glucagon-like peptide-1 (7-36): A physiological incretin in man
3. Insulinotropic action of glucagon-like peptide-1 (7-37) in diabetic and nondiabetic subjects
4. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects
5. Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: One of several potential extrapancreatic sites of GLP-1 action
6. Glucagon-like peptide 1: A potent glycogenic hormone
7. Glucagon-like peptide [7-36 amide] increases insulin stimulated glucose uptake in isolated fat adipocytes
8. Potent glycogenic effect of GLP-1 (7-36) amide in rat skeletal muscle
9. Preserved GLP-1 effects on glycogen synthase activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats
10. Extrapancreatic action of truncated glucagon-like peptide-1 in Otsuka Long-Evans Tokushima fatty rats, an animal model for non-insulin-dependent diabetes mellitus
11. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase A in hepatocytes from normal and diabetic rats
12. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal
13. Antidiabetogenic effect of glucagon-like peptide-1 (7-36 amide) in normal subjects and patients with diabetes
14. Failure of GLP-1 (7-36) amide to affect glycogenesis in rat skeletal muscle
15. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones
16. Insulinotropic hormone GLP-1 appears not to augment insulin-mediated glucose uptake in young men during euglycemia
17. Effect of glucagon-like peptide 1 (7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes
18. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus
19. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults
20. Diabetes in the elderly
21. Metabolic alterations in middle-aged and elderly obese patients with type 2 diabetes
22. Manual feedback technique for control of glucose concentration
23. Arterial versus venous samplings on analysis of glucose kinetics in man
24. Effect of aging and diabetes on the enteroinsular axis
25. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
26. GLP-1 in NIDDM